Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high risk diffuse large B-cell lymphoma and positive interim PET after 4 cycles of R-CHOP-14.

DOI number 10.58109/fh7f-3b31
Publisher Australasian Leukaemia and Lymphoma Group (ALLG)
Creator(s)

Australasian Leukaemia and Lymphoma Group (ALLG)

Mark Hertzberg (Westmead Hospital)

Rodney Hicks (Peter MacCallum Cancer Centre)
Dataset Individual participant data (IPD) in aggregate form
Description of Dataset

Dataset includes:

  • Full data of 149 patients with a poor prognosis of diffuse large b-cell lymphoma was analysed (151 eligible patients – 3 patients withdrawing consent)
  • Safety population analyzed was 151 patients (all patients that received at least 1 dose)
  • ECOG performance status was assessed for all 151 patients (ECOG taken pre-treatment)
  • Objective to demonstrated effectiveness of using PET/CT scanning to determine further treatment post 4 cycles of R-CHOP-14 treatment
    • PET/CT positive patients receiving R-ICE x 3 followed by Z-BEAM/ASCT + IF-RT
    • PET/CT negative patients recevigin R_CHOP-14 x 2
  • Interim PET response of 143 patients (after 4 cycles of R-CHOP 14

Data of Follow Up of 143 patients went for a minimum length of 0.065 months, and a maximum length of 65.22 (as months since interim PET scan)
Funding

Australasian Leukaemia and Lymphoma Group (ALLG)
Subject (ANZSRC Category)

Predictive and prognostic markers
ANZCTR Reference ACTRN12609001077257
Publication(s)
Dataset Access

Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to info@allg.org.au
Memberships
Participate in a Trial
Memberships
Clinical Trials & Research
NHL07
NHL24